CoChat
Sign Up
Cited by 26

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis

Pelzer, Uwe, Blanc, Jean-Frédéric, Melisi, Davide, Cubillo, Antonio, Von Hoff, Daniel D, Wang-Gillam, Andrea, Chen, Li-Tzong, Siveke, Jens T, Wan, Yin, Solem, Caitlyn T, Botteman, Marc F, Yang, Yoojung, de Jong, Floris A, Hubner, Richard A·2017·British Journal of Cancer
DOI 10.1038/bjc.2017.67PMC PMC5482729
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.2017.67

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Utility threshold plot for Q-TWiST (nal-IRI+5-FU/LV vs 5-FU/LV) at 12 months in intent to treat cohort. (A) The x-axis represents the utility for time after disease progression (REL) and y-axis represents the utility for TOX time. Both U(TOX) and U(REL) vary from 0 to 1, with U(TWiST) held at 1. The diagonal bands of different colours represent varying Q-TWiST gains by level of utility for TOX and REL. To understand the Q-TWiST gain associated with a given combination of U(REL) and U(TOX), one must select the corresponding values of U(REL) and U(TOX) on the x-axis and y-axis, respectively. The intersection of these two values inside the plot indicates which band of Q-TWiST gain the result from this combination belong. (B) The x-axis represents the utility for time after disease progression (REL) and y-axis represents the utility for TOX time. Both U(TOX) and U(REL) vary from 0 to 1, with U(TWiST) held at 1. The diagonal bands of different colour represent varying relative Q-TWiST gains by level of utility for TOX and REL, calculated by dividing the absolute Q-TWiST gain by the mean survival in the 5-FU/LV group. To understand relative Q-TWiST gain associated with a given combination of U(REL) and U(TOX), one must select the corresponding values of U(REL) and U(TOX) on the x-axis and y-axis, respectively. The intersection of these two values inside the plot indicates which band of relative Q-TWiST gain the result from this combination belong. *Not significant when utility of relapse is close to 1 and utility of AE is close to 0. REL=relapse; TOX=toxicity.
Figure 1 Utility threshold plot for Q-TWiST (nal-IRI+5-FU/LV vs 5-FU/LV) at 12 months in intent to treat cohort. (A) The x-axis represents the utility for time after disease progression (REL) and y-axis represents the utility for TOX time. Both U(TOX) and U(REL) vary from 0 to 1, with U(TWiST) held at 1. The diagonal bands of different colours represent varying Q-TWiST gains by level of utility for TOX and REL. To understand the Q-TWiST gain associated with a given combination of U(REL) and U(TOX), one must select the corresponding values of U(REL) and U(TOX) on the x-axis and y-axis, respectively. The intersection of these two values inside the plot indicates which band of Q-TWiST gain the result from this combination belong. (B) The x-axis represents the utility for time after disease progression (REL) and y-axis represents the utility for TOX time. Both U(TOX) and U(REL) vary from 0 to 1, with U(TWiST) held at 1. The diagonal bands of different colour represent varying relative Q-TWiST gains by level of utility for TOX and REL, calculated by dividing the absolute Q-TWiST gain by the mean survival in the 5-FU/LV group. To understand relative Q-TWiST gain associated with a given combination of U(REL) and U(TOX), one must select the corresponding values of U(REL) and U(TOX) on the x-axis and y-axis, respectively. The intersection of these two values inside the plot indicates which band of relative Q-TWiST gain the result from this combination belong. *Not significant when utility of relapse is close to 1 and utility of AE is close to 0. REL=relapse; TOX=toxicity.CC BY-NC-SA · PubMed Central
Figure 2 Differences in Q-TWiST between nal-IRI+5-FU/LV vs 5-FU/LV at 3, 6, 9, 12 and 15 Months of Follow-Up.
Figure 2 Differences in Q-TWiST between nal-IRI+5-FU/LV vs 5-FU/LV at 3, 6, 9, 12 and 15 Months of Follow-Up.CC BY-NC-SA · PubMed Central
Figure 3 Quality-adjusted time without symptoms of disease progression or toxicity differences in months (5-FU/LV vs nal-IRI+5-FU/LV) among subgroups. KPS=Karnofsky performance status; tx=treatment.
Figure 3 Quality-adjusted time without symptoms of disease progression or toxicity differences in months (5-FU/LV vs nal-IRI+5-FU/LV) among subgroups. KPS=Karnofsky performance status; tx=treatment.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 21

  1. Chen L-T, Von Hoff DD, Li C-P, Wang-Gillam A, Bodoky G, Dean AP, Shan Y-S, Jameson GS, Macarulla T, Lee K-H (2015) Expanded analyses of napoli-1: phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol 33: 234. · DOI
  2. Cole BF, Gelber RD (1995) A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. Stat Med 14: 1771–1784. · DOI
  3. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem J, Conroy T (2015) Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26: v56–v68. · DOI
  4. Fairclough DL (2010) Design and Analysis of Quality of Life Studies in Clinical Trials. CRC Press. · DOI
  5. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49 (6): 1374–1403. · DOI
  6. Gelber RD, Goldhirsch A, Cole BF Group IBCS (1993) Evaluation of effectiveness: Q-TWiST. Cancer Treat Rev 19: 73–84. · DOI
  7. Goldstein D, Maraghi E, Hassan R, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J (2014) Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. ASCO Annu Meeting Proc 2014: 178.
  8. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481. · DOI · Paper page
  9. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J (2006) Health state utilities for metastatic breast cancer. BJC 95: 683–690. · DOI
  10. Melisi D, Calvetti L, Frizziero M, Tortora G (2014) Pancreatic cancer: systemic combination therapies for a heterogeneous disease. Curr Pharm Des 20: 6660–6669. · DOI
  11. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J (2008) Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6: 1. · DOI
  12. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U (2015) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 32: 2423–2429. · DOI
  13. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74: 2913–2921. · DOI · Paper page
  14. Reni M, Wan Y, Solem C, Whiting S, Ji X, Botteman M (2014) Quality-adjusted survival with combination nab-paclitaxel+ gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. J Med Econ 17: 338–346. · DOI
  15. Revicki DA, Feeny D, Hunt TL, Cole BF (2006) Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res 15: 411–423. · DOI
  16. Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D, Cancer BLG (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43: 205–217. · DOI
  17. Solem C, Wan Y, Botteman M (2014) Systematic review of the Q-TWiST in oncology. Value Health 17: A194–A195. · DOI
  18. Swinburn P, Lloyd A, Nathan P, Choueiri TK, Cella D, Neary MP (2010) Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin 26: 1091–1096. · DOI
  19. Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D (2013) Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol 4: 56. · DOI
  20. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A (2014) Pancreatic adenocarcinoma, version 2.2014. J Natl Compr Canc Netw 12: 1083–1093. · DOI
  21. Tolley K, Goad C, Yi Y, Maroudas P, Haiderali A, Thompson G (2013) Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ 14: 749–759. · DOI

Cited by

Sorted by citations

See all 26

Metadata

Authors
Pelzer, U., Blanc, J.-F., Melisi, D., Cubillo, A., Von Hoff, D. D., Wang-Gillam, A., Chen, L.-T., Siveke, J. T., Wan, Y., Solem, C. T., Botteman, M. F., Yang, Y., de Jong, F. A., & Hubner, R. A.
Venue
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Published
2017-03-28
Volume
116
Issue
10
Pages
1247-1253
ISSN
  • 0007-0920
  • 1532-1827
DOI
10.1038/bjc.2017.67
PMC
PMC5482729
Cited by
26
References
1
Language
en
Licence
creativecommons.org/licenses/by-nc-sa/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. https://app.cochat.ai/papers/10.1038/bjc.2017.67
The paper
Pelzer, U., Blanc, J.-F., Melisi, D., Cubillo, A., Von Hoff, D. D., Wang-Gillam, A., Chen, L.-T., Siveke, J. T., Wan, Y., Solem, C. T., Botteman, M. F., Yang, Y., de Jong, F. A., & Hubner, R. A. (2017). Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. British Journal of Cancer. https://doi.org/10.1038/bjc.2017.67